Abraham Morgentaler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Abraham Morgentaler has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Brandon C. Stahl
Division of Urology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
2 shared publicationsErnani Luis Rhoden
Men's Health Boston, Division of Urology, Harvard Medical School, Boston, MA, USA
2 shared publicationsYizhong Yin
Division of Urology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
2 shared publicationsDesiderio Avila
Department of Urology, Baylor Medical College, Houston, Texas
1 shared publication- Ernani Luis Rhoden
Urology Division at Santa Casa de Misericórdia Hospital and Moinhos de Vento Hospital (HMV)
1 shared publication Larry I. Lipshultz
Department of Urology, Baylor Medical College, Houston, Texas
1 shared publication
Latest Publications
- 1 April 2011
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 185 (4) , 1256-1261
Testosterone Therapy in Men With Untreated Prostate Cancer
A history of prostate cancer has been a longstanding contraindication to the use of testosterone therapy due to the belief that higher serum testosterone causes more rapid prostate cancer growth. Recent evidence has called this paradigm into question. In this study we investigate the effect of testosterone therapy in men with untreated prostate cancer. We report the results of prostate biopsies, serum prostate specific antigen and prostate volume in symptomatic testosterone deficient cases receiving testosterone therapy while undergoing active surveillance for prostate cancer. A total of 13 symptomatic testosterone deficient men with untreated prostate cancer received testosterone therapy for a median of 2.5 years (range 1.0 to 8.1). Mean age was 58.8 years. Gleason score at initial biopsy was 6 in 12 men and 7 in 1. Mean serum concentration of total testosterone increased from 238 to 664 ng/dl (p <0.001). Mean prostate specific antigen did not change with testosterone therapy (5.5 ± 6.4 vs 3.6 ± 2.6 ng/ml, p = 0.29). Prostate volume was unchanged. Mean number of followup biopsies was 2. No cancer was found in 54% of followup biopsies. Biopsies in 2 men suggested upgrading, and subsequent biopsies in 1 and radical prostatectomy in another indicated no progression. No local prostate cancer progression or distant disease was observed. Testosterone therapy in men with untreated prostate cancer was not associated with prostate cancer progression in the short to medium term. These results are consistent with the saturation model, ie maximal prostate cancer growth is achieved at low androgen concentrations. The longstanding prohibition against testosterone therapy in men with untreated or low risk prostate cancer or treated prostate cancer without evidence of metastatic or recurrent disease merits reevaluation.
- 1 April 2011
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 185 (4) , 1256-1261
Testosterone Therapy in Men With Untreated Prostate Cancer
A history of prostate cancer has been a longstanding contraindication to the use of testosterone therapy due to the belief that higher serum testosterone causes more rapid prostate cancer growth. Recent evidence has called this paradigm into question. In this study we investigate the effect of testosterone therapy in men with untreated prostate cancer. We report the results of prostate biopsies, serum prostate specific antigen and prostate volume in symptomatic testosterone deficient cases receiving testosterone therapy while undergoing active surveillance for prostate cancer. A total of 13 symptomatic testosterone deficient men with untreated prostate cancer received testosterone therapy for a median of 2.5 years (range 1.0 to 8.1). Mean age was 58.8 years. Gleason score at initial biopsy was 6 in 12 men and 7 in 1. Mean serum concentration of total testosterone increased from 238 to 664 ng/dl (p <0.001). Mean prostate specific antigen did not change with testosterone therapy (5.5 ± 6.4 vs 3.6 ± 2.6 ng/ml, p = 0.29). Prostate volume was unchanged. Mean number of followup biopsies was 2. No cancer was found in 54% of followup biopsies. Biopsies in 2 men suggested upgrading, and subsequent biopsies in 1 and radical prostatectomy in another indicated no progression. No local prostate cancer progression or distant disease was observed. Testosterone therapy in men with untreated prostate cancer was not associated with prostate cancer progression in the short to medium term. These results are consistent with the saturation model, ie maximal prostate cancer growth is achieved at low androgen concentrations. The longstanding prohibition against testosterone therapy in men with untreated or low risk prostate cancer or treated prostate cancer without evidence of metastatic or recurrent disease merits reevaluation.
- 1 January 2010
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 7 (1_Part_1) , 277-283
Symptomatic Response Rates to Testosterone Therapy and the Likelihood of Completing 12 Months of Therapy in Clinical Practice
Despite increasing medical interest in testosterone therapy (TTh) for men with testosterone deficiency (TD) there is limited information regarding subjective response rates and acceptability of medium- to long-term TTh in routine clinical practice. To evaluate results in a consecutive series of men in clinical practice treated with TTh. A chart review was performed for a consecutive series of men for whom TTh was initiated over 1 year for a clinical diagnosis of TD. A diagnosis of TD was based on the presence of symptoms and on laboratory evaluation indicating total testosterone (Rhoden EL, and Morgentaler A. Symptomatic response rates to testosterone therapy and the likelihood of completing 12 months of therapy in clinical practice.
- 1 January 2010
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 7 (1_Part_1) , 277-283
Symptomatic Response Rates to Testosterone Therapy and the Likelihood of Completing 12 Months of Therapy in Clinical Practice
Despite increasing medical interest in testosterone therapy (TTh) for men with testosterone deficiency (TD) there is limited information regarding subjective response rates and acceptability of medium- to long-term TTh in routine clinical practice. To evaluate results in a consecutive series of men in clinical practice treated with TTh. A chart review was performed for a consecutive series of men for whom TTh was initiated over 1 year for a clinical diagnosis of TD. A diagnosis of TD was based on the presence of symptoms and on laboratory evaluation indicating total testosterone (Rhoden EL, and Morgentaler A. Symptomatic response rates to testosterone therapy and the likelihood of completing 12 months of therapy in clinical practice.
- 1 November 2007
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 4 (6) , 1757-1762
Subjective Sexual Response to Testosterone Replacement Therapy Based on Initial Serum Levels of Total Testosterone
Introduction: Testosterone replacement therapy (TRT) has been shown to be beneficial for men with hypogonadism. However, it is unknown how well hypogonadal men respond to TRT based on the severity of testosterone deficiency. Aim: To determine subjective sexual response rates to TRT based on initial serum testosterone values, with particular interest in men with “low-normal” levels of total testosterone (TT). Main Outcome Measures: Subjective responses to TRT in the domains of erectile dysfunction, libido, orgasm, and morning erections. Methods: A retrospective study was performed of 211 men with sexual symptoms of hypogonadism who underwent TRT. All men had either low values of TT (<300 ng/dL) or free testosterone (FT) (<1.5 ng/dL). The cohort was divided into three groups based on initial TT levels: Group 1: 0–200 ng/dL (N=26; 12.3%); Group 2: 201–300 ng/dL (N=64; 30.3%); Group 3: 301 ng/dL or greater (N=121; 57.3%). Improvement in erectile function was determined prior to addition of any other treatment (e.g., phosphodiesterase type 5 inhibitors). The mean follow-up was 9 months (range 3–36 months). Results: The mean age was 55.2 years. Testosterone gel was used in approximately two-thirds of each group. Improvement in libido was reported in 61.5%, 96.6%, and 29.8% for Groups 1, 2, and 3, respectively (P <0.001). Improvement in erectile function was noted in 46.2%, 45.3%, and 73.6% for Groups 1, 2, and 3, respectively (P <0.001). At time of last follow-up, the percentage of men continuing with TRT was 73.1%, 57.8%, and 58.7% for Groups 1, 2, and 3, respectively (P =nonsignificant). Conclusions: These preliminary data suggest that men with sexual symptoms of hypogonadism respond well to TRT across a wide range of initial TT values, including men with low-normal TT levels. These men may have low bioavailable levels of testosterone that are not reflected in TT values.
- 1 November 2007
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 4 (6) , 1757-1762
Subjective Sexual Response to Testosterone Replacement Therapy Based on Initial Serum Levels of Total Testosterone
Introduction: Testosterone replacement therapy (TRT) has been shown to be beneficial for men with hypogonadism. However, it is unknown how well hypogonadal men respond to TRT based on the severity of testosterone deficiency. Aim: To determine subjective sexual response rates to TRT based on initial serum testosterone values, with particular interest in men with “low-normal” levels of total testosterone (TT). Main Outcome Measures: Subjective responses to TRT in the domains of erectile dysfunction, libido, orgasm, and morning erections. Methods: A retrospective study was performed of 211 men with sexual symptoms of hypogonadism who underwent TRT. All men had either low values of TT (<300 ng/dL) or free testosterone (FT) (<1.5 ng/dL). The cohort was divided into three groups based on initial TT levels: Group 1: 0–200 ng/dL (N=26; 12.3%); Group 2: 201–300 ng/dL (N=64; 30.3%); Group 3: 301 ng/dL or greater (N=121; 57.3%). Improvement in erectile function was determined prior to addition of any other treatment (e.g., phosphodiesterase type 5 inhibitors). The mean follow-up was 9 months (range 3–36 months). Results: The mean age was 55.2 years. Testosterone gel was used in approximately two-thirds of each group. Improvement in libido was reported in 61.5%, 96.6%, and 29.8% for Groups 1, 2, and 3, respectively (P <0.001). Improvement in erectile function was noted in 46.2%, 45.3%, and 73.6% for Groups 1, 2, and 3, respectively (P <0.001). At time of last follow-up, the percentage of men continuing with TRT was 73.1%, 57.8%, and 58.7% for Groups 1, 2, and 3, respectively (P =nonsignificant). Conclusions: These preliminary data suggest that men with sexual symptoms of hypogonadism respond well to TRT across a wide range of initial TT values, including men with low-normal TT levels. These men may have low bioavailable levels of testosterone that are not reflected in TT values.
- Top Cited Papers
- 29 January 2004
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 350 (5) , 482-492
Risks of Testosterone-Replacement Therapy and Recommendations for Monitoring
Although some reports suggest that testosterone-replacement therapy may provide benefits for aging men, considerable controversy remains regarding indications for its use. Neither large-scale nor long-term studies have been initiated, in part because of theoretical concern regarding the risks associated with testosterone therapy, especially the possible stimulation of prostate cancer. This article discusses what is known (and not known) about the risks of testosterone-replacement therapy and provides recommendations for monitoring men who are receiving testosterone.
- 29 January 2004
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 350 (5) , 482-492
Top Cited PapersRisks of Testosterone-Replacement Therapy and Recommendations for Monitoring
Although some reports suggest that testosterone-replacement therapy may provide benefits for aging men, considerable controversy remains regarding indications for its use. Neither large-scale nor long-term studies have been initiated, in part because of theoretical concern regarding the risks associated with testosterone therapy, especially the possible stimulation of prostate cancer. This article discusses what is known (and not known) about the risks of testosterone-replacement therapy and provides recommendations for monitoring men who are receiving testosterone.
- 1 January 2004
- Published by Springer Nature in International Journal Of Impotence Research
- Vol. 16 (1) , 95-97
Treatment of testosterone-induced gynecomastia with the aromatase inhibitor, anastrozole
Gynecomastia is an unusual side effect associated with testosterone replacement therapy (TRT) that has been traditionally treated with surgery, radiation, or discontinuation of testosterone supplementation. We report here our experience with two cases of gynecomastia in men undergoing TRT who were successfully treated with the aromatase inhibitor anastrozole.
- 1 January 2004
- Published by Springer Nature in International Journal Of Impotence Research
- Vol. 16 (1) , 95-97
Treatment of testosterone-induced gynecomastia with the aromatase inhibitor, anastrozole
Gynecomastia is an unusual side effect associated with testosterone replacement therapy (TRT) that has been traditionally treated with surgery, radiation, or discontinuation of testosterone supplementation. We report here our experience with two cases of gynecomastia in men undergoing TRT who were successfully treated with the aromatase inhibitor anastrozole.
- Open Access
- 2 January 2002
- Published by Wiley in Journal of Andrology
- Vol. 23 (1) , 64-70
p53 and Fas Are Sequential Mechanisms of Testicular Germ Cell Apoptosis
Testicular germ cell apoptosis in the cryptorchid testis is induced by abdominal heat stress. p53‐dependent apoptosis appears responsible for the initial phase of germ cell loss in experimental cryptorchidism based on a 3‐day delay of apoptosis in p53−1− mice. However, the mechanisms underlying the subsequent p53‐independent apoptosis have not been identified. Although studies have suggested that Fas plays a role in testicular germ cell apoptosis, no direct evidence has been shown. To test the hypothesis that Fas is involved in testicular germ cell apoptosis and is responsible for the p53‐independent phase of apoptosis in the cryptorchid testis, p53−1, Ipr/lpr (a spontaneous mutation in the Fas gene, which causes autoimmune disease) double‐mutant mice were generated and unilateral cryptorchidism was induced in these mice. It was found that testicular weight reduction and germ cell apoptosis were delayed by an additional 3 days, and the Fas production increased in the time frame of p53‐independent apoptosis in the experimental cryptorchid testis of wild‐type mice. These results suggest that Fas is involved in testicular germ cell apoptosis, and that Fas‐dependent apoptosis is responsible for the p53‐independent phase of germ cell apoptosis in the cryptorchid testis. The cascade of testicular germ cell apoptosis in response to heat stress implies the existence of sequential quality control mechanisms in spermatogenesis.
- 2 January 2002
- Published by Wiley in Journal of Andrology
- Vol. 23 (1) , 64-70
Open Accessp53 and Fas Are Sequential Mechanisms of Testicular Germ Cell Apoptosis
Testicular germ cell apoptosis in the cryptorchid testis is induced by abdominal heat stress. p53‐dependent apoptosis appears responsible for the initial phase of germ cell loss in experimental cryptorchidism based on a 3‐day delay of apoptosis in p53−1− mice. However, the mechanisms underlying the subsequent p53‐independent apoptosis have not been identified. Although studies have suggested that Fas plays a role in testicular germ cell apoptosis, no direct evidence has been shown. To test the hypothesis that Fas is involved in testicular germ cell apoptosis and is responsible for the p53‐independent phase of apoptosis in the cryptorchid testis, p53−1, Ipr/lpr (a spontaneous mutation in the Fas gene, which causes autoimmune disease) double‐mutant mice were generated and unilateral cryptorchidism was induced in these mice. It was found that testicular weight reduction and germ cell apoptosis were delayed by an additional 3 days, and the Fas production increased in the time frame of p53‐independent apoptosis in the experimental cryptorchid testis of wild‐type mice. These results suggest that Fas is involved in testicular germ cell apoptosis, and that Fas‐dependent apoptosis is responsible for the p53‐independent phase of germ cell apoptosis in the cryptorchid testis. The cascade of testicular germ cell apoptosis in response to heat stress implies the existence of sequential quality control mechanisms in spermatogenesis.
- 4 March 1999
- Published by Wiley in Journal of Andrology
- Vol. 20 (2) , 189-195
Testis and Temperature: An Historical, Clinical, and Research Perspective
- 4 March 1999
- Published by Wiley in Journal of Andrology
- Vol. 20 (2) , 189-195
Testis and Temperature: An Historical, Clinical, and Research Perspective